Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 20/20 | 1.00 |
| ▸ | GIPR | P48546 | 14/20 | 1.00 |
| ▸ | VIPR2 | P41587 | 4/20 | 1.00 |
| ▸ | GLP1R | P43220 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.81 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.81 |
| ▸ | DUSP2 | Q05923 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0893 SCHEMBL29363684 | 0.89 | GCGR (1.00) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| Mk-0893 SCHEMBL675777 | 0.89 | GCGR (1.00) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| Mk-0893 SCHEMBL2355321 | 0.89 | GCGR (1.00) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL19137241 | 0.87 | GCGR (0.77) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2645995 | 0.85 | GCGR (1.00) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2662897 | 0.85 | GCGR (1.00) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2667959 | 0.83 | GCGR (0.73) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2667515 | 0.83 | GCGR (0.73) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2642984 | 0.83 | GCGR (0.78) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2794351 | 0.83 | GCGR (0.87) | GCGRGIPRVIPR2GLP1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383869-B1 | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3177614-B1 | FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3177282-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3383388-B1 | ARYL ACYLSULFONAMIDES AS BLT1 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10968193-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3177285-B1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10450309-B2 | Aryl sulfonamides as BLT1 antagonists | Merch Sharp & Dohme Corp. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10370368-B2 | Aryl acylsulfonamides as BLT1 antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10336733-B2 | Aryl acylsulfonamides as BLT1 antagonists | Merk Sharp & Dohme Corp. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10131651-B2 | [7,6]-fused bicyclic antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20090176854-A1 | N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009011872-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1756064-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1756064-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1756064-A2 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121097-A2 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121097-A2 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PC, GOT2, PNLIP | GCGR 188/4885GIPR 205/4885VIPR2 1017/4885 |
| US-10968193-B2 | Antidiabetic bicyclic compounds | GPR119, GPR65, GLP1R | GCGR 11/4885GIPR 10/4885VIPR2 193/4885 |
| US-10131651-B2 | [7,6]-fused bicyclic antidiabetic compounds | GPR119, GPR27, GPR55 | GCGR 12/4885GIPR 7/4885VIPR2 275/4885 |
| US-20090176854-A1 | N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance | GOT2, GOT1, IAPP | GCGR 189/4885GIPR 177/4885VIPR2 2173/4885 |
| US-10450309-B2 | Aryl sulfonamides as BLT1 antagonists | LTB4R2, LTB4R, LTC4S | GCGR 338/4885GIPR 555/4885VIPR2 851/4885 |
| US-10370368-B2 | Aryl acylsulfonamides as BLT1 antagonists | LTB4R2, LTB4R, LTC4S | GCGR 413/4885GIPR 626/4885VIPR2 759/4885 |
| US-10336733-B2 | Aryl acylsulfonamides as BLT1 antagonists | LTB4R2, LTB4R, LTC4S | GCGR 431/4885GIPR 697/4885VIPR2 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.